(Q40747284)

23 September 2017

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma (English)

1 reference

23 September 2017

angiogenesis inhibitor

1 reference

1

1 reference

23 September 2017

16

1 reference

23 September 2017

Clelia Palladino

7

0 references

Ilaria Bacigalupo

Ilaria Bacigalupo

5

0 references

Donatella Valdembri

Donatella Valdembri

13

0 references

M Falchi

Mario Falchi

12

0 references

Federico Bussolino

Federico Bussolino

15

0 references

Barbara Ensoli

Barbara Ensoli

17

0 references

Giovanni Rezza

14

Giovanni Rezza

1 reference

23 September 2017

Giovanni Barillari

2

1 reference

23 September 2017

Elena Toschi

3

1 reference

23 September 2017

Davide Carlei

4

1 reference

23 September 2017

Sara Baccarini

6

1 reference

23 September 2017

Patrizia Leone

8

1 reference

23 September 2017

Roberto Bugarini

9

1 reference

23 September 2017

Laura Malavasi

10

1 reference

23 September 2017

Aurelio Cafaro

11

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

23 September 2017

8

1 reference

inferred from page(s)

published in

Nature Medicine

1 reference

23 September 2017

8

1 reference

23 September 2017

225-232

1 reference

23 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0302-225

23 September 2017

0 references

cites work

Reactivation and role of HHV-8 in Kaposi's sarcoma initiation

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Monoclonal Origin of Multicentric Kaposi's Sarcoma Lesions

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Serum Concentrations of Fibroblast Growth Factor 2 Are Increased in HIV Type 1-Infected Patients and Inversely Related to Survival Probability

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Tumor targeting with a selective gelatinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Mechanism of paclitaxel activity in Kaposi's sarcoma.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Permanent cell line expressing human factor VIII-related antigen established by hybridization

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Identification of human herpesvirus 8-specific cytotoxic T-cell responses.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

CD8+ cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0302-225

7 January 2021

Identifiers

DOI

10.1038/NM0302-225

1 reference

23 September 2017

1 reference